Reuters logo
BRIEF-Ose Immunotherapeutics partners with Gercor to conduct a combination phase 2 trial of Tedopi for pancreatic cancer
September 6, 2017 / 5:39 AM / 3 months ago

BRIEF-Ose Immunotherapeutics partners with Gercor to conduct a combination phase 2 trial of Tedopi for pancreatic cancer

Sept 6 (Reuters) - OSE IMMUNOTHERAPEUTICS SA:

* OSE IMMUNOTHERAPEUTICS PARTNERS WITH ONCOLOGY PHYSICIAN NETWORK GERCOR TO CONDUCT A COMBINATION PHASE 2 TRIAL OF TEDOPI® FOR PANCREATIC CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below